Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Raised by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report) by 6.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,366 shares of the biotechnology company’s stock after purchasing an additional 917 shares during the period. Pallas Capital Advisors LLC’s holdings in Viking Therapeutics were worth $267,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Retirement Group LLC lifted its stake in Viking Therapeutics by 75.0% in the 2nd quarter. Retirement Group LLC now owns 2,100 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 900 shares in the last quarter. Cetera Advisor Networks LLC purchased a new stake in Viking Therapeutics in the 2nd quarter worth about $36,000. Engineers Gate Manager LP purchased a new stake in Viking Therapeutics in the 1st quarter worth about $37,000. Envestnet Asset Management Inc. purchased a new stake in Viking Therapeutics in the 2nd quarter worth about $53,000. Finally, Great West Life Assurance Co. Can purchased a new stake in Viking Therapeutics in the 1st quarter worth about $63,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Greg Zante sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the completion of the transaction, the chief financial officer now owns 180,730 shares in the company, valued at approximately $3,235,067. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Greg Zante sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $17.90, for a total transaction of $268,500.00. Following the completion of the transaction, the chief financial officer now owns 180,730 shares in the company, valued at approximately $3,235,067. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sarah Kathryn Rouan sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $28.05, for a total value of $701,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 374,079 shares of company stock worth $9,729,653. 4.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

VKTX has been the subject of several research analyst reports. Truist Financial increased their price objective on Viking Therapeutics from $32.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Viking Therapeutics in a research report on Tuesday, March 26th. StockNews.com raised Viking Therapeutics to a “sell” rating in a research report on Friday, February 9th. Jefferies Financial Group began coverage on Viking Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $110.00 target price on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

Get Our Latest Stock Analysis on VKTX

Viking Therapeutics Price Performance

Shares of NASDAQ VKTX opened at $77.35 on Wednesday. The business’s 50-day simple moving average is $53.60 and its 200-day simple moving average is $28.22. Viking Therapeutics, Inc. has a 52 week low of $8.28 and a 52 week high of $99.41.

Viking Therapeutics (NASDAQ:VKTXGet Free Report) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same period last year, the business posted ($0.26) earnings per share. Equities analysts forecast that Viking Therapeutics, Inc. will post -1.1 earnings per share for the current year.

Viking Therapeutics Profile

(Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTXFree Report).

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.